A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or i...

Autor Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O.
Vydáno v ESMO Open (2021)

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

Autor Sartor, O., Heinrich, D., Mariados, N., Méndez Vidal, M. J., Keizman, D., Thellenberg Karlsson, C., Peer, A., Procopio, G., Frank, S. J., Pulkkanen, K., Rosenbaum, E., Severi, S., Trigo Perez, J. M., Wagner, V., Li, R., Nordquist, L. T.
Vydáno v Ann Oncol (2017)